Under construction – not a live service

Skip to content

Frontlight Research

Trial site

Royal Bournemouth Hospital

Bournemouth, BH7 7DW, United KingdomNot linked to an institution yet

28running trials
15closed trials

The trials here

What the 43 trials at this site are about, from their registry records.

Conditions: Coronary artery disease11 trials
Multiple myeloma6 trials
Childhood cancers4 trials
Heart failure3 trials
High blood pressure3 trials
Atrial fibrillation2 trials
Gastric and oesophageal cancer2 trials
Prostate cancer2 trials
Stroke2 trials
Triple-negative breast cancer2 trials
Acute myeloid leukaemia1 trial
Chronic lymphocytic leukaemia1 trial
and 14 more
Phase: Phase 317 trials
Phase 24 trials
Phase 2/32 trials
Status: Completed14 trials
Recruiting14 trials
Active, not recruiting11 trials
Enrolling by invitation2 trials
Not yet recruiting1 trial
Terminated1 trial
Lead sponsor: Imperial College London3 trials
Janssen Research & Development, LLC3 trials
Aarhus University Hospital Skejby2 trials
Amgen2 trials
Pfizer2 trials
and 27 more

Running trials

Enrolling by invitation
Optical Coherence Tomography in Acute Vessel Evaluation
NCT07422688· Aarhus University Hospital Skejby· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459· Phase 3· Amgen· Source
Active, not recruiting
FARAPULSE Workflow Assessment Registry
NCT06656884· Boston Scientific Corporation· Source
Recruiting
Multivessel Balloon Occlusion to Investigate Obstructive Coronary Artery Disease and aNgina
NCT06400290· Imperial College London· Source
Contact: Peter O'Kane
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575· Phase 3· Pfizer· Source
Recruiting
Liquid Biopsy System Intracoronary Blood Sampling and Analysis to Characterise Disease Biomarkers in Patients With Coronary Disease
NCT06259019· PlaqueTec Ltd· Source
Contact: Principal Investigator
Recruiting
A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis
NCT06461208· Phase 3· King's College London· Source
Contact: Safa Al-Shamma
Active, not recruiting
Predicting the Risk of Non-culprit Coronary Artery Disease After a Heart Attack
NCT05781087· Guy's and St Thomas' NHS Foundation Trust· Source
Recruiting
RCT of Implantable Defibrillators in Patients With Non Ischemic Cardiomyopathy, Scar and Severe Systolic Heart Failure
NCT05568069· University Hospital Southampton NHS Foundation Trust· Source
Contact: Chris Critoph
Recruiting
Met Non Small Cell Cancer Registry (MOMENT)
NCT05376891· EMD Serono Research & Development Institute, Inc.· Source
Contact: Tom Geldart (principal investigator)
Recruiting
A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT05085028· Phase 3· Imperial College London· Source
Contact: Tom Geldart
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236· Phase 3· Pfizer· Source
Enrolling by invitation
Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting
NCT04451044· Philips Clinical & Medical Affairs Global· Source
Active, not recruiting
First in Human Clinical Investigation of the FIRE1 System in Heart Failure Patients (FUTURE-HF)
NCT04203576· Foundry Innovation & Research 1, Limited (FIRE1)· Source
Recruiting
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
NCT04116502· Phase 3· University of Birmingham· Source
Contact: Natalia Morelli
Recruiting
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
NCT03740893· Phase 2· Institute of Cancer Research, United Kingdom· Source
Contact: Christophe Verstegen
Active, not recruiting
Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer
NCT04067713· University College, London· Source
Active, not recruiting
A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
NCT03899337· Phase 2· University of Birmingham· Source
Recruiting
Renal Adjuvant MultiPle Arm Randomised Trial
NCT03288532· Phase 3· University College, London· Source
Contact: Tom Geldart (principal investigator)
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
NCT03171311· Aarhus University Hospital Skejby· Source
Recruiting
The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)
NCT03562169· Phase 3· University of Leeds· Source
Contact: Rachel Hall
Recruiting
Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer
NCT04050345· Royal Marsden NHS Foundation Trust· Source
Contact: Bryony Eccles (principal investigator)
Recruiting
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
NCT03150576· Phase 2/3· Cambridge University Hospitals NHS Foundation Trust· Source
Contact: Maria Cidon (principal investigator)
Active, not recruiting
A Study of the ReCor Medical Paradise System in Clinical Hypertension
NCT02649426· ReCor Medical, Inc.· Source
Active, not recruiting
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
NCT02170090· Phase 3· Universitätsklinikum Hamburg-Eppendorf· Source
Active, not recruiting
Minimal SN Tumor Burden
NCT01942603· European Organisation for Research and Treatment of Cancer - EORTC· Source
Active, not recruiting
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
NCT00268476· Phase 2/3· Medical Research Council· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Recruiting
Understanding the Variation of Modern Endoscopic Ultrasound Use in Patients With Oesophageal Cancer (VALUE)
NCT06440174· University Hospital Southampton NHS Foundation Trust· Source
Contact: Ben Lindfield
Completed
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957· Phase 3· Janssen Research & Development, LLC· Source
Completed
OptimiZation Of Lipid Lowering Therapies Using a Decision Support System In Patients With Acute Coronary Syndrome.
NCT05844566· Imperial College London· Source
Completed
A Placebo-controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention for the Relief of Stable Angina
NCT05142215· Mid and South Essex NHS Foundation Trust· Source
Recruiting
iCorMicA - Stratified Medicine in Angina
NCT04674449· NHS Greater Glasgow and Clyde· Source
Contact: Colin Berry, MBChB, PhD
Completed
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
NCT04543617· Phase 3· Hoffmann-La Roche· Source
Completed
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
NCT03872401· Phase 3· Amgen· Source
Completed
The Late Presenter Treatment Optimisation Study
NCT03696160· Phase 3· NEAT ID Foundation· Source
Completed
Selinexor, Cyclophosphamide and Prednisone in Myeloma
NCT06212596· Phase 2· University of Leeds· Source
Completed
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
NCT03412565· Phase 2· Janssen Research & Development, LLC· Source
Completed
Confirm Rx Insertable Cardiac Monitor SMART Registry
NCT03505801· Abbott Medical Devices· Source
Completed
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
NCT03268954· Phase 3· Takeda· Source
Completed
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
NCT03277105· Phase 3· Janssen Research & Development, LLC· Source
Completed
Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke
NCT02898610· Phase 3· University College Dublin· Source
Completed
SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System
NCT02439775· Medtronic Vascular· Source

Site data: ClinicalTrials.govUpdated 12 Nov 2026

Report an error

Under construction, not live – Royal Bournemouth Hospital: trial site – Frontlight Research